Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Business Wire•07/10/2026•16:05 ET
0
Key Highlights
- ➤Three-year follow-up showed sustained 1.9 D improvement in maximum corneal curvature
- ➤29% of treated eyes gained two or more visual-acuity lines by year three
- ➤20% of treated eyes gained three or more visual-acuity lines by year three
- ➤No serious or treatment-related adverse events through three years
- ➤92% of 38 study eyes completed the year-three visit
Expert Statements
Thomas Burns, Chairman and Chief Executive Officer of Glaukos
“These long-term results further reinforce the potential of Epioxa to provide durable clinical benefits for patients living with keratoconus”
Thomas Burns, Chairman and Chief Executive Officer of Glaukos
“The sustained improvements in corneal shape and visual acuity, coupled with an excellent long-term safety profile, reinforce our view that Epioxa represents a transformative treatment advancement for keratoconus patients.”
Glaukos Announces Positive Three-Year Epioxa(®) Results Demonstrating Durable Clinical Outcomes in Keratoconus
Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment
Get started
Create a free account to read the full story.